U. Creutzig, M. Van-den-heuvel-eibrink, and B. Gibson, Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel, Blood, vol.120, issue.16, pp.3187-3205, 2012.
DOI : 10.1182/blood-2012-03-362608

H. Fernandez, Z. Sun, and X. Yao, Anthracycline Dose Intensification in Acute Myeloid Leukemia, New England Journal of Medicine, vol.361, issue.13, pp.1249-1259, 2009.
DOI : 10.1056/NEJMoa0904544

G. Kaspers and C. Zwaan, Pediatric acute myeloid leukemia: towards high-quality cure of all patients, Haematologica, vol.92, issue.11, pp.1519-1532, 2007.
DOI : 10.3324/haematol.11203

S. Lipshultz, S. Colan, and R. Gelber, Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood, New England Journal of Medicine, vol.324, issue.12, pp.808-815, 1991.
DOI : 10.1056/NEJM199103213241205

K. Nysom, K. Holm, and S. Lipsitz, Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia., Journal of Clinical Oncology, vol.16, issue.2, pp.545-550, 1998.
DOI : 10.1200/JCO.1998.16.2.545

K. Sorensen, G. Levitt, C. Bull, and J. Chessells, Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity., Journal of Clinical Oncology, vol.15, issue.1, pp.61-68, 1997.
DOI : 10.1200/JCO.1997.15.1.61

J. Berbis, G. Michel, and A. Baruchel, Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort), International Journal of Epidemiology, vol.44, issue.1, pp.1-9, 2014.
DOI : 10.1093/ije/dyu031

URL : https://hal.archives-ouvertes.fr/hal-01064613

L. Kremer, H. Van-der-pal, and M. Offringa, Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review, Annals of Oncology, vol.13, issue.6, pp.819-829, 2002.
DOI : 10.1093/annonc/mdf167

S. Lipshultz, M. Adams, and S. Colan, Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions: A Scientific Statement From the American Heart Association, Circulation, vol.128, issue.17, pp.1927-1995, 2013.
DOI : 10.1161/CIR.0b013e3182a88099

S. Shankar, N. Marina, and M. Hudson, Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group, PEDIATRICS, vol.121, issue.2, pp.387-396, 2008.
DOI : 10.1542/peds.2007-0575

L. Deley, M. Leblanc, T. Shamsaldin, A. Raquin, M. Lacour et al., Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Soci??t?? Fran??aise d???Oncologie P??diatrique, Journal of Clinical Oncology, vol.21, issue.6, pp.1881074-1081, 2003.
DOI : 10.1200/JCO.2003.04.100

P. Temming, A. Qureshi, and J. Hardt, Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom, Pediatric Blood & Cancer, vol.266, issue.4, pp.625-630, 2011.
DOI : 10.1002/pbc.22908

U. Creutzig, S. Diekamp, and M. Zimmermann, Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer, pp.651-662, 2007.

W. Leung, M. Hudson, and D. Strickland, Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.18, issue.18, pp.3273-3279, 2000.
DOI : 10.1200/JCO.2000.18.18.3273

G. Michel, E. Gluckman, and H. Esperou-bourdeau, Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Soci??t?? Fran??aise de Greffe de Moelle., Journal of Clinical Oncology, vol.12, issue.6, pp.1217-1222, 1994.
DOI : 10.1200/JCO.1994.12.6.1217